Suchergebnisse - "Pavlovsky, Miguel"

PubPharm (57)

1

Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort : Safety and Efficacy Analysis

enthalten in: Clinical lymphoma, myeloma & leukemia | 2024

von Mela Osorio, M. | Moiraghi, B. | Osycka, M. | +12

2

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia : A study by ERIC, the European research initiative on CLL

enthalten in: American journal of hematology | 2023

von Visentin, A. | Chatzikonstantinou, T. | Scarfò, L. | +98

3

Phase 3 SELENE study : ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma

enthalten in: Blood advances | 2023

von Nastoupil, L. | Hess, G. | Pavlovsky, M. | +24

CommentIn: Blood Adv. 2023 Nov 28;7(22):7139-7140. - PMID 38015493

4

Results of VOICE : a global survey of disease-specific knowledge and perspectives of real-world patients with CLL

enthalten in: Blood advances | 2023

von Tam, C. | Pinilla-Ibarz, J. | Castillo, C. | +10

5

Inequalities in access to treatment in Argentina : Differences in management of CLL and multiple myeloma?

enthalten in: Seminars in hematology | 2023

von Mela Osorio, M. | Pavlovsky, C. | Pavlovsky, M.

6

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

enthalten in: Journal of hematology & oncology | 2023

von Pavlovsky, C. | Vasconcelos Cordoba, B. | Sanchez, M. | +21

7

Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal

enthalten in: Journal of hematology & oncology | 2023

von Pavlovsky, C. | Vasconcelos Cordoba, B. | Sanchez, M. | +21

8

COVID-19 in subjects at risk participating in clinical trials during the pandemic in Argentina

enthalten in: Medicina | 2023

von Ibelli, F. | Bozzo, R. | Iannantuono, M. | +21

9

In-depth characterization of NK cell markers from CML patients who discontinued tyrosine kinase inhibitor therapy

enthalten in: Frontiers in immunology | 2023

von Sanchez, M. | Vasconcelos Cordoba, B. | Pavlovsky, C. | +19

10

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

enthalten in: Frontiers in oncology | 2023

von Sarapura Martinez, V. | Buonincontro, B. | Cassarino, C. | +12

1
2
3
4
5
6
Nächster »
[6]